Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

MADRID — Thou­sands of ES­MO del­e­gates on Sun­day gave a stand­ing ova­tion to con­fir­ma­to­ry tri­al da­ta show­ing Seagen and Astel­las Phar­ma’s Pad­cev in com­bi­na­tion with Mer­ck …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER